Literature DB >> 15605411

Identification and functional characterization of five novel mutant alleles in 58 Italian patients with Gaucher disease type 1.

Snjezana Miocić1, Mirella Filocamo, Silvia Dominissini, Anna Lisa E Montalvo, Kristian Vlahovicek, Marta Deganuto, Raffaella Mazzotti, Roberta Cariati, Bruno Bembi, Maria Gabriela Pittis.   

Abstract

Gaucher disease (GD) is the most frequent lysosomal glycolipid storage disorder due to an autosomal recessive deficiency of acid beta-glucosidase characterized by the accumulation of glucocerebroside. In this work we carried out the molecular analysis of the glucocerebrosidase gene (GBA) in 58 unrelated patients with GD type 1. We identified five novel genetic alterations: three missense changes c.187G>A (p.D63N), c.473T>G (p.I158S), c.689T>A (p.V230E), a gene-pseudogene recombinant allele and a non-pseudogene-derived complex allele [c.1379G>A;c.1469A>G] encoding [p.G460D;p.H490R]. All mutant alleles were present as compound heterozygotes in association with c.1226A>G (p.N409S), the most common mutation in GD1. The missense mutant proteins were expressed in vitro in COS-1 cells and analyzed by enzyme activity, protein processing and intracellular localization. Functional studies also included the c.662C>T (p.P221L) mutation recently reported in the Spanish GD population (Montfort et al., 2004). The missense mutant alleles retained an extremely low residual enzyme activity with respect to wild type; the complex allele expressed no activity. Processing of the mutant proteins was unaltered except for c.473T>G which was differently glycosylated due to the exposition of an additional glycosylation site. Immunofluorescence studies showed that protein trafficking into the lysosomes was unaffected in all cases. Finally, the characterization of the novel recombinant allele identified a crossover involving the GBA gene and pseudogene between intron 5 and exon 7. (c) 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2005        PMID: 15605411     DOI: 10.1002/humu.9301

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  6 in total

1.  Newborn screening for lysosomal storage disorders in hungary.

Authors:  Judit Wittmann; Eszter Karg; Sàndor Turi; Elisa Legnini; Gyula Wittmann; Anne-Katrin Giese; Jan Lukas; Uta Gölnitz; Michael Klingenhäger; Olaf Bodamer; Adolf Mühl; Arndt Rolfs
Journal:  JIMD Rep       Date:  2012-03-21

Review 2.  Type 2 Gaucher disease: phenotypic variation and genotypic heterogeneity.

Authors:  N Gupta; I M Oppenheim; E F Kauvar; N Tayebi; E Sidransky
Journal:  Blood Cells Mol Dis       Date:  2010-09-28       Impact factor: 3.039

3.  Stabilization of Glucocerebrosidase by Active Site Occupancy.

Authors:  Fredj Ben Bdira; Wouter W Kallemeijn; Saskia V Oussoren; Saskia Scheij; Boris Bleijlevens; Bogdan I Florea; Cindy P A A van Roomen; Roelof Ottenhoff; Marielle J F M van Kooten; Marthe T C Walvoort; Martin D Witte; Rolf G Boot; Marcellus Ubbink; Herman S Overkleeft; Johannes M F G Aerts
Journal:  ACS Chem Biol       Date:  2017-05-22       Impact factor: 5.100

4.  Functional analysis of 11 novel GBA alleles.

Authors:  Erika Malini; Serena Grossi; Marta Deganuto; Camillo Rosano; Rossella Parini; Silvia Dominisini; Roberta Cariati; Stefania Zampieri; Bruno Bembi; Mirella Filocamo; Andrea Dardis
Journal:  Eur J Hum Genet       Date:  2013-09-11       Impact factor: 4.246

5.  Accurate Molecular Diagnosis of Gaucher Disease Using Clinical Exome Sequencing as a First-Tier Test.

Authors:  Stefania Zampieri; Silvia Cattarossi; Eleonora Pavan; Antonio Barbato; Agata Fiumara; Paolo Peruzzo; Maurizio Scarpa; Giovanni Ciana; Andrea Dardis
Journal:  Int J Mol Sci       Date:  2021-05-24       Impact factor: 5.923

6.  Analysis of glucocerebrosidase (GBA) gene mutations in Iranian patients with Gaucher disease.

Authors:  Hadi Mozafari; Mohammad Tghikhani; Zohreh Rahimi; Asad Vaisi Raygani; Shahla Ansari; Shohreh Khatami; Mohammad Reza Alaei; Reza Saghiri
Journal:  Iran J Child Neurol       Date:  2021
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.